Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

The promiscuous 10%?

Mark A Bellis, Karen Hughes, John R Ashton

    Journal of Epidemiology and Community Health
    |October 16, 2004
    PubMed
    Summary

    No abstract available in PubMed .

    Related Experiment Videos

    Related Concept Videos

    You might also read

    Related Articles

    Articles linked to this work by shared authors, journal, and citation graph.

    Sort by
    Same author

    Artificial intelligence in critical synthesis of public health responses to violence: A novel application to UK violence prevention policy.

    Public health·2026
    Same author

    Mapping the evidence on outcomes of childhood out-of-home care: A scoping review of reviews.

    PloS one·2026
    Same author

    The Awareness and Adoption of UK Physical Activity Guidelines by Socio-Demographics: A National Cross-Sectional Survey in Wales.

    International journal of environmental research and public health·2026
    Same author

    Supportive enriched environment improves recovery from persistent motor and cognitive impairments after severe traumatic brain injury.

    Frontiers in behavioral neuroscience·2026
    Same author

    A novel chimeric coronavirus spike vaccine combining SARS-CoV-2 RBD and scaffold domains from HKU-1 elicits potent neutralising antibody responses.

    NPJ vaccines·2025
    Same author

    Safety and Immunogenicity of a Severe Acute Respiratory Syndrome Coronavirus 2 Spike Subunit Vaccine Stabilized in the Prefusion Conformation by a Second-Generation Molecular Clamp and Evaluated in Adults Aged 18-55 Years: A Randomized, Double-Blind, Active Comparator, Phase I Trial.

    The Journal of infectious diseases·2025